Repository logo
 
Publication

Effect of carbamylated erythropoietin in a chronic model of TNBS-induced colitis

2023-09Journal article Open access
Simple item page
dc.contributor.authorSilva, Inês
dc.contributor.authorGomes, Mário
dc.contributor.authorAlípio, Carolina
dc.contributor.authorVitoriano, Jéssica
dc.contributor.authorEstarreja, João
dc.contributor.authorMendes, Priscila
dc.contributor.authorPinto, Rui
dc.contributor.authorMateus, Vanessa
dc.date.accessioned2023-10-09T10:40:20Z
dc.date.available2023-10-09T10:40:20Z
dc.date.issued2023-09
dc.descriptionThis work was funded by IDI&CA_Polytechnic Institute of Lisbon [grant number IPL/2022/CoIbu-Ils_ESTeSL].pt_PT
dc.descriptionFCT_UIDB/05608/2020. FCT_UIDP/05608/2020.pt_PT
dc.description.abstractBackground: Inflammatory bowel disease (IBD) is a public health issue with a growing prevalence, which can be divided into two phenotypes, namely Crohn's disease (CD) and ulcerative colitis (UC). Currently, used therapy is based only on symptomatic and/or palliative pharmacological approaches. These treatments seek to induce and maintain remission of the disease and ameliorate its secondary effects; however, they do not modify or reverse the underlying pathogenic mechanism. Therefore, it is essential to investigate new potential treatments. Carbamylated erythropoietin (cEPO) results from the modification of the Erythropoietin (EPO) molecule, reducing cardiovascular-related side effects from the natural erythropoiesis stimulation. cEPO has been studied throughout several animal models, which demonstrated an anti-inflammatory effect by decreasing the production of several pro-inflammatory cytokines. Aim: This study aimed to evaluate the efficacy and safety of cEPO in a chronic TNBS-induced colitis model in rodents. Methods: Experimental colitis was induced by weekly intrarectal (IR) administrations of 1% TNBS for 5 weeks in female CD-1 mice. Then, the mice were treated with 500 IU/kg/day or 1000 IU/kg/day of cEPO through intraperitoneal injections for 14 days. Results: cEPO significantly reduced the concentration of alkaline phosphatase (ALP), fecal hemoglobin, tumor necrosis factor (TNF)-α, and interleukin (IL)-10. Also, it demonstrated a beneficial influence on the extra-intestinal manifestations, with the absence of significant side effects of its use. Conclusion: Considering the positive results from cEPO in this experiment, it may arise as a new possible pharmacological approach for the future management of IBD.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSilva I, Gomes M, Alípio C, Vitoriano J, Estarreja J, Mendes P, Mateus V, et al. Effect of carbamylated erythropoietin in a chronic model of TNBS-induced colitis. Biomedicines. 2023;11(9):2497.pt_PT
dc.identifier.doi10.3390/biomedicines11092497pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16538
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationIPL/2022/CoIbu-Ils_ESTeSLpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2227-9059/11/9/2497pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectTNBS-induced colitispt_PT
dc.subjectCarbamylated erythropoietinpt_PT
dc.subjectInflammatory bowel diseasept_PT
dc.subjectRodentspt_PT
dc.subjectIPL/2022/CoIbu-Ils_ESTeSLpt_PT
dc.subjectFCT_UIDB/05608/2020pt_PT
dc.subjectFCT_UIDP/05608/2020pt_PT
dc.titleEffect of carbamylated erythropoietin in a chronic model of TNBS-induced colitispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue9pt_PT
oaire.citation.startPage2497pt_PT
oaire.citation.titleBiomedicinespt_PT
oaire.citation.volume11pt_PT
person.familyNameda Silva
person.familyNameEstarreja
person.familyNameRodrigues Gomes Mendes
person.familyNamePinho Mateus
person.givenNameInês Filipa Janeiro da Silva
person.givenNameJoão
person.givenNamePriscila
person.givenNameVanessa Alexandra
person.identifier.ciencia-idC010-323F-3266
person.identifier.ciencia-idEB19-EDA2-704B
person.identifier.ciencia-id6A16-5C18-F10B
person.identifier.ciencia-id5A12-571D-AD6A
person.identifier.orcid0000-0001-7049-2512
person.identifier.orcid0000-0002-8283-3174
person.identifier.orcid0000-0002-0013-3140
person.identifier.orcid0000-0002-3204-3772
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication995e1831-ff5b-49e7-a6e3-8bc692212204
relation.isAuthorOfPublicationd16a20d0-ac73-4989-b83d-abeab53139f7
relation.isAuthorOfPublicationb02faa18-658e-4edc-b846-7c0b3646414c
relation.isAuthorOfPublication406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscoveryd16a20d0-ac73-4989-b83d-abeab53139f7

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Effect of carbamylated erythropoietin in a chronic model of TNBS-induced colitis.pdf
Size:
3.12 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos